These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 22382383)
1. Effects of rosuvastatin and atorvastatin on renal function: meta-analysis. Wu Y; Wang Y; An C; Dong Z; Liu H; Zhang Y; Zhang M; An F Circ J; 2012; 76(5):1259-66. PubMed ID: 22382383 [TBL] [Abstract][Full Text] [Related]
2. Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis. Savarese G; Musella F; Volpe M; Paneni F; Perrone-Filardi P Int J Cardiol; 2013 Sep; 167(6):2482-9. PubMed ID: 22633671 [TBL] [Abstract][Full Text] [Related]
3. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Milionis HJ; Rizos E; Kostapanos M; Filippatos TD; Gazi IF; Ganotakis ES; Goudevenos J; Mikhailidis DP; Elisaf MS Curr Med Res Opin; 2006 Jun; 22(6):1123-31. PubMed ID: 16846545 [TBL] [Abstract][Full Text] [Related]
5. Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes. Mori Y; Kuriyama G; Tanaka T; Tajima N Endocrine; 2009 Dec; 36(3):412-8. PubMed ID: 19834827 [No Abstract] [Full Text] [Related]
6. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Thongtang N; Ai M; Otokozawa S; Himbergen TV; Asztalos BF; Nakajima K; Stein E; Jones PH; Schaefer EJ Am J Cardiol; 2011 Feb; 107(3):387-92. PubMed ID: 21257003 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Faergeman O; Hill L; Windler E; Wiklund O; Asmar R; Duffield E; Sosef F; Cardiology; 2008; 111(4):219-28. PubMed ID: 18434729 [TBL] [Abstract][Full Text] [Related]
8. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. Wlodarczyk J; Sullivan D; Smith M Am J Cardiol; 2008 Dec; 102(12):1654-62. PubMed ID: 19064019 [TBL] [Abstract][Full Text] [Related]
9. Risk of incident diabetes among patients treated with statins: population based study. Carter AA; Gomes T; Camacho X; Juurlink DN; Shah BR; Mamdani MM BMJ; 2013 May; 346():f2610. PubMed ID: 23704171 [TBL] [Abstract][Full Text] [Related]
10. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Insull W; Ghali JK; Hassman DR; Y As JW; Gandhi SK; Miller E; Mayo Clin Proc; 2007 May; 82(5):543-50. PubMed ID: 17493418 [TBL] [Abstract][Full Text] [Related]
11. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Marais AD; Raal FJ; Stein EA; Rader DJ; Blasetto J; Palmer M; Wilpshaar W Atherosclerosis; 2008 Mar; 197(1):400-6. PubMed ID: 17727860 [TBL] [Abstract][Full Text] [Related]
12. Statin wars: emphasis on potency vs event reduction and safety? Lavie CJ; Milani RV; O'Keefe JH Mayo Clin Proc; 2007 May; 82(5):539-42. PubMed ID: 17493417 [No Abstract] [Full Text] [Related]
13. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Saku K; Zhang B; Noda K; Circ J; 2011; 75(6):1493-505. PubMed ID: 21498906 [TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial). Kaya A; Kurt M; Tanboğa IH; Işik T; Ekinci M; Aksakal E; Kaya Y; Topçu S; Sevimli S Acta Cardiol; 2013 Oct; 68(5):489-94. PubMed ID: 24283110 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW; Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention. Liu Y; Liu YH; Tan N; Chen JY; Zhou YL; Li LW; Duan CY; Chen PY; Luo JF; Li HL; Wei-Guo PLoS One; 2014; 9(10):e111124. PubMed ID: 25357250 [TBL] [Abstract][Full Text] [Related]
18. High coronary plaque load: a heavy burden. de Graaf MA; Jukema JW Eur Heart J; 2013 Nov; 34(41):3168-70. PubMed ID: 23966308 [No Abstract] [Full Text] [Related]
19. [Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): -- the PATROL trial]. Saku K; Zhang B; Noda K Nihon Naika Gakkai Zasshi; 2011 Dec; 100(12):3679-86. PubMed ID: 22338904 [No Abstract] [Full Text] [Related]
20. First head-to-head study comparing rosuvastatin and atorvastatin effects on the treatment of atherosclerosis. Cardiovasc J Afr; 2008; 19(1):60. PubMed ID: 18320096 [No Abstract] [Full Text] [Related] [Next] [New Search]